scholarly journals Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST Study

2008 ◽  
Vol 22 (5) ◽  
pp. 1124-1135 ◽  
Author(s):  
J. Häggström ◽  
A. Boswood ◽  
M. O'Grady ◽  
O. Jöns ◽  
S. Smith ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
Survival Times ◽  
Naturally Occurring

scholarly journals Vasovagal tonus index in dog with myxomatous mitral valve disease

2017 ◽  
Vol 37 (10) ◽  
pp. 1181-1186 ◽  
Author(s):  
Bruna C. Brüler ◽  
Amália T. Giannico ◽  
Gustavo Dittrich ◽  
Marlos G. Sousa
Keyword(s):  
Internal Medicine ◽  
Heart Failure ◽  
Heart Rate ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Cardiac Remodeling ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
Rr Intervals ◽  
Naturally Occurring

ABSTRACT: The vasovagal tonus index (VVTI) is a useful and assessable index, obtained from standard ECG recordings, that is used to estimate heart rate variability (HRV), and may provide valuable information regarding the likelihood of progression into congestive heart failure (CHF). In this paperwork, we investigated how the vasovagal tonus index (VVTI) behaves in dogs with naturally-occurring myxomatous mitral valve disease (MMVD) Electrocardiographic (ECG) recordings and echocardiographic data of 120 patients diagnosed with MMVD were reviewed. The VVTI was calculated from twenty consecutive RR intervals for each dog enrolled in the study. Lower VVTI values were found in MMVD patients in American College of Veterinary Internal Medicine (ACVIM) stage C compared with stages B1 and B2. Values were also lower in patients with severe cardiac remodeling. When a cut-off value of 6.66 is used, VVTI was able to discriminate MMVD patients in stage C from B1 and B2 dogs with a sensitivity of 70 per cent and a specificity of 77 per cent. MMVD dogs in which VVTI is lower than 6.66 are 30% more likely to develop congestive heart failure (CHF).

scholarly journals Blood lactate increases with the progression of mitral valve disease in dogs

2018 ◽  
Vol 38 (9) ◽  
pp. 1781-1786
Author(s):  
Jorge Cardoso Silva-Filho ◽  
Marlos G. Sousa ◽  
Evandro Zacché Pereira ◽  
Edna M.G. Ortiz ◽  
Rodrigo P. Franco ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Blood Lactate ◽  
Cardiac Remodeling ◽  
Mitral Valve Disease ◽  
Lactate Concentration ◽  
Tissue Perfusion ◽  
Valve Disease ◽  
Cross Sectional

ABSTRACT: In dogs with congestive heart failure, the upregulated sympathetic tone causes vasoconstriction that impairs peripheral blood supply, therefore causing the accumulation of lactate. In this prospective cross-sectional study with a longitudinal component, blood lactate was quantified in 10 healthy and 34 myxomatous mitral valve disease (MMVD) dogs to investigate its potential use as a diagnostic and prognostic biomarker. While there were no differences in lactate concentration between control animals and stages B1 (3.31±0.62mmol/L) and B2 (3.32±0.46mmol/L) dogs, significant differences were found between healthy (2.50±0.69mmol/L) and both C (3.99±0.47mmol/L) and D (6.97±1.23mmol/L) animals. When a cut-off of 3.35mmol/L was used, lactate was able to distinguish dogs with normal and remodeled hearts with a sensitivity of 78.2% and specificity of 63.6%. Also, significant correlations existed between lactate and indicators of cardiac remodeling. Finally, animals with blood lactate <3.5mmol/L carried a better prognosis when compared with dogs in which lactate was >5.0mmol/L. Our results suggest that the progression of MMVD results in accumulation of lactate within the bloodstream, which is likely attributable to the impaired peripheral tissue perfusion. In MMVD dogs, blood lactate may be used as a surrogate for cardiac remodeling, and an increased concentration is associated with a worse prognosis regarding the time to evolve into congestive heart failure.

Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: The PREDICT cohort study

2012 ◽  
Vol 14 (1) ◽  
pp. 193-202 ◽  
Author(s):  
Caryn A. Reynolds ◽  
Dorothy Cimino Brown ◽  
John E. Rush ◽  
Philip R. Fox ◽  
Thaibihn P. Nguyenba ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Cohort Study ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
First Onset

scholarly journals Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model

2017 ◽  
Vol 6 (1) ◽  
pp. 1350088 ◽  
Author(s):  
Vicky K. Yang ◽  
Kerry A. Loughran ◽  
Dawn M. Meola ◽  
Christine M. Juhr ◽  
Kristen E. Thane ◽  
...  
Keyword(s):  
Heart Failure ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Canine Model ◽  
Valve Disease ◽  
Naturally Occurring

scholarly journals Depleted Myocardial Coenzyme Q10 in Cavalier King Charles Spaniels with Congestive Heart Failure Due to Myxomatous Mitral Valve Disease

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 161
Author(s):  
Liselotte B. Christiansen ◽  
Maria J. Reimann ◽  
Anne Marie V. Schou-Pedersen ◽  
Steen Larsen ◽  
Jens Lykkesfeldt ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Coenzyme Q10 ◽  
Mitral Valve Disease ◽  
Defense Mechanisms ◽  
Citrate Synthase ◽  
Left Ventricular ◽  
Valve Disease ◽  
Tissue Samples

Congestive heart failure (CHF) has been associated with depleted myocardial coenzyme Q10 (Q10) concentrations in human patients. The aim of this study was to investigate associations between myocardial Q10 concentrations and myxomatous mitral valve disease (MMVD) severity in dogs. Furthermore, citrate synthase (CS) activity was analysed to determine if a reduction in myocardial Q10 was associated with mitochondrial depletion in the myocardium. Thirty Cavalier King Charles spaniels (CKCS) in MMVD stages B1 (n = 11), B2 (n = 5) and C (n = 14) according to the American College of Veterinary Internal Medicine (ACVIM) guidelines and 10 control (CON) dogs of other breeds were included. Myocardial Q10 concentration was analysed in left ventricular tissue samples using HPLC-ECD. CKCS with congestive heart failure (CHF; group C) had significantly reduced Q10 concentrations (median, 1.54 µg/mg; IQR, 1.36–1.94), compared to B1 (2.76 µg/mg; 2.10–4.81, p < 0.0018), B2 (3.85 µg/mg; 3.13–4.46, p < 0.0054) and CON dogs (2.8 µg/mg; 1.64–4.88, p < 0.0089). CS activity was comparable between disease groups. In conclusion, dogs with CHF due to MMVD had reduced myocardial Q10 concentrations. Studies evaluating antioxidant defense mechanisms as a therapeutic target for treatment of CHF in dogs are warranted.

Sign in / Sign up

Export Citation Format

Share Document